Antibody molecules to pd-1 and uses thereof
作者： Walter A. Blattler , Catherine Anne Sabatos-Peyton , Arlene Helen Sharpe , Jennifer Marie Mataraza , Gordon James Freeman
DOI:
关键词:
摘要: Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody can be used treat, prevent and/or diagnose cancerous or infectious conditions and disorders.
glgoo.top参考文章(686)
Shuji Ozaki, Masaaki Kosaka, Shingo Wakatsuki, Masahiro Abe, Yasuo Koishihara, Toshio Matsumoto, Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24 Blood. ,vol. 90, pp. 3179- 3186 ,(1997) , 10.1182/BLOOD.V90.8.3179
Jeroen Elassaiss-Schaap, Gradus Johannes Dulos, Gregory John Carven, Bioassays for determining pd-1 modulation ,(2011)
Sian Henson, Arne Akbar, Method to improve the immune function of t cells ,(2012)
Linda Liang, Robert H. Pierce, Michael Bigler, Patricia Bourne, Antibodies that bind to human programmed death ligand 1 (pd-l1) ,(2013)
Giorgio Caravatti, Clive Mccarthy, Robin Alec Fairhurst, Frédéric Stauffer, Heinrich Rueeger, Pascal Furet, Frank Hans Seiler, Oxazolidin-2-one compounds and uses thereof as pi3ks inhibitors ,(2013)
Scott E. Strome, Lieping Chen, Detection of antibodies specific for B7-H1 in subjects with diseases or pathological conditions mediated by activated T cells ,(2003)
Pablo D Garcia, John L Langowski, Jocelyn Holash, Matthew Burger, Richard Zang, Tatiana Zavorotinskaya, Christie Fanton, Abdel Saci, Joseph Growney, K. Gary Vanasse, The Pan-PIM Kinase Inhibitor LGH447 Shows Activity In PIM2-Dependent Multiple Myeloma and In AML Models Blood. ,vol. 122, pp. 1666- 1666 ,(2013) , 10.1182/BLOOD.V122.21.1666.1666
Asim Amin, Elizabeth R. Plimack, Jeffrey R. Infante, Marc S. Ernstoff, Brian I. Rini, David F. McDermott, Jennifer J. Knox, Sumanta Kumar Pal, Martin Henner Voss, Padmanee Sharma, Christian K. Kollmannsberger, Daniel Yick Chin Heng, Jennifer L. Spratlin, Yun Shen, John F. Kurland, Paul Gagnier, Hans J. Hammers, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. ,vol. 32, pp. 5010- 5010 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.5010
G. M. Grass, J. R. Robinson, Sustained- and controlled-release drug delivery systems Drugs and the pharmaceutical sciences. ,vol. 40, pp. 635- 671 ,(1978)
Vijay K. Kuchroo, Valerie Dardalhon, Ana Carrizosa Anderson, Methods for modulating a population of myeloid-derived suppressor cells and uses thereof ,(2009)